CompletedNCT04980807
Observational Study of Neuromuscular Function in CMT Type 1&2 and Healthy Controls
Studying Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NMD Pharma A/S
- Principal Investigator
- Henning Andersen, MD, PhDAarhus University Hospital
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2022
Study locations (2)
- Ohio State University, Columbus, Ohio, United States
- Aarhus University Hospital, Aarhus, Jutland, Denmark
Collaborators
Aarhus University Hospital · Ohio State University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04980807 on ClinicalTrials.govOther trials for Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07038239Genotype/Phenotype Correlation of MORC2 MutationsHospices Civils de Lyon
- RECRUITINGNCT06203093Charcot-Marie-Tooth Disease (CMT) Biological Sample Collection for IPSC Generation and BiobankingNew York Stem Cell Foundation Research Institute
- RECRUITINGNCT05902351Natural History Study for Charcot Marie Tooth DiseaseHereditary Neuropathy Foundation
See all trials for Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons →